Secunderabad Chronicle

Interstitial Lung Disease market size is expected to grow at a moderate rate due to the emerging therapies by major pharma giants during the study period (2018-30)

 Breaking News
  • No posts were found

Interstitial Lung Disease market size is expected to grow at a moderate rate due to the emerging therapies by major pharma giants during the study period (2018-30)

August 17
19:32 2021
Interstitial Lung Disease market size is expected to grow at a moderate rate due to the emerging therapies by major pharma giants during the study period (2018-30)
Interstitial Lung Disease Market
The introduction of Pirfenidone, ATYR1923, and others are expected to give the Interstitial Lung Disease market a significant boost in the forecast period 2021-30 in the 7MM.

DelveInsight’s Interstitial Lung Disease market report provides a comprehensive understanding of Interstitial Lung Disease, historical and forecasted epidemiology, and Interstitial Lung Disease market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). In addition, the report also discusses current Interstitial Lung Disease treatment practices and algorithms, Interstitial Lung Disease market dynamics, and unmet medical needs.

Some of the Key Highlights from the Interstitial Lung Disease Market Report

  • According to the American Lung Association, Interstitial Lung Disease is a general term for a wide range of lung disorders that result in scarring or fibrosis. Among the overall number of Interstitial Lung Diseases, there are more than 200 different conditions.

  • Key players, such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Bristol Myers Squibb, and others are involved in the development of therapies for Interstitial Lung Disease (ILD) treatment. 

  • The FDA granted Priority Review to Pirfenidone for the treatment of unclassifiable Interstitial Lung Disease (UILD) in January 2021 after accepting Roche’s supplemental New Drug Application (sNDA).

  • OATD-01 (OncoArendi Therapeutics) is the first chitinase inhibitor to enter clinical development. It is a potent, selective, orally active small-molecule inhibitor. Galapagos and OncoArendi Therapeutics signed an exclusive collaboration and license agreement for the global development and commercialization of OATD-01 in November 2020.

  • ATYR1923 (aTyr Pharma) is a potential first-in-class, novel, disease-modifying therapy for patients suffering from Interstitial Lung Disease.

For better understanding about the disease, request for sample @ Stages of Interstitial Lung Disease

The Interstitial Lung Disease market report covers the current treatment methods, developing medications, Interstitial Lung Disease market share of individual therapies, current and anticipated Interstitial Lung Disease market size from 2018 to 2030 segmented by seven major markets.

Interstitial Lung Disease: Overview

Interstitial Lung Disease (ILD) is an umbrella term used for a variety of disorders that induce lung scarring (fibrosis). Scarring in the lungs produces rigidity, making it harder to breathe and get oxygen into the bloodstream. Interstitial Lung Disease causes irreparable lung damage that worsens over time. Interstitial lung disease can affect anyone, even children. Genetics, certain drugs, and medical procedures such as radiation or chemotherapy can all increase the risk of or cause ILDs.

Interstitial Lung Disease Epidemiology Segmentation

The Interstitial Lung Disease report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Interstitial Lung Disease Total Incidence

  • Interstitial Lung Disease Gender-Specific Cases

  • Interstitial Lung Disease Subtype-Specific Cases

  • Interstitial Lung Disease Diagnosed and Treatable Cases

Interstitial Lung Disease Treatment Landscape

The Interstitial Lung Disease treatment plan includes supportive therapies such as supplemental oxygen, pulmonary rehabilitation, measures to relieve symptoms such as cough, anxiety, depression, dyspnea, and treatment of co-morbid conditions, as well as treatment of co-morbid conditions (such as anemia, sleep-disordered breathing, GER, infectious complications). Apart from there are some FDA-approved drugs also such as Ofev (nintedanib) that are used to treat Interstitial Lung Disease.

Interstitial Lung Disease Market

Key pharmaceutical companies such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Bristol Myers Squibb, and others are expected to launch new therapies in the Interstitial Lung Disease market.

The introduction of Pirfenidone, OATD-01, ATYR1923, and others are expected to give the Interstitial Lung Disease market a significant boost in the forecast period 2021-30 in the 7MM.

Get a detailed analysis of the interstitial lung disease market @ Interstitial Lung Disease Market Size

Interstitial Lung Disease Pipeline Therapies and Key Companies 

  • Pirfenidone: Roche 

  • ATYR1923: aTyr Pharma

  • OATD-01: OncoArendi Therapeutics

  • Abatacept: Bristol Myers Squibb

Table of Contents 

1.

Report Introduction

2.

Interstitial Lung Disease (ILD) Market Overview at a Glance

3.

Disease Background and Overview: Interstitial Lung Disease (ILD)

4.

Interstitial Lung Disease Epidemiology and Patient Population

5.

Interstitial Lung Disease (ILD): Country-Wise Epidemiology

6.

Interstitial Lung Disease Treatment & Medical Practices

7.

Interstitial Lung Disease Key Emerging Therapies

8.

Interstitial Lung Disease (ILD): Market Size

9.

7MM Interstitial Lung Disease (ILD): Country-Wise Market Analysis

10.

Interstitial Lung Disease Market Drivers

11.

Interstitial Lung Disease Market Barriers

12.

Appendix

13.

Report Methodology

14.

DelveInsight Capabilities

15.

Disclaimer

16.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Interstitial Cystitis Market

Get comprehensive historical and forecast analysis of Interstitial Cystitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Lipella Pharmaceuticals, Purdue Pharma/Alivio Therapeutics, Seikagaku Corporation, Kyorin Holdings, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles